Plain Language Summary {#S0001}
======================

Perfluorocarbon liquid (PFCL) is often used in retinal detachment surgery. Sometimes, the PFCL can pass through a retinal tear and get stuck under the retina. If this happens close to the part of the retina responsible for central vision (macula), it can cause significant loss of vision due to mechanical effects and toxic effects. In those cases, the subretinal PFCL cannot be left under the retina. Traditionally, the PFCL is removed directly (aspirated) if needed. In this article, the authors describe a surgical case where they did not remove the PFCL, but instead, successfully displaced it towards a less critical area of the retina in order to protect the macula. Although this technique is not new, it is little known and, theoretically, might be less risky than the traditional approach of direct removal.

Introduction {#S0002}
============

Retained subretinal perfluorocarbon liquid (PFCL) is a known complication of using PFCL in retinal detachment (RD) surgery. This complication may considerably reduce visual acuity (VA) if it occurs near the macula. Moreover, if the PFCL reaches the subfoveal area, it can cause local damage to the retinal pigmented epithelium (RPE) and photoreceptors, leading to permanent decrease in VA.[@CIT0001] Current evidence suggests removal of subretinal PFCL if VA is significantly impaired.[@CIT0002] As concluded by Liu et al[@CIT0002] in their review of the management of subfoveal PFCL, no specific technique is currently recommended, mainly because of the lack of randomized or controlled trials, the limited number of cases reported, combined with the uniqueness of each case.

Case Report {#S0003}
===========

A 61-year-old woman consulted initially for reduced vision in her right eye with a best-corrected visual acuity (BCVA) of "counting fingers". "Fundus examination showed a temporal bullous macula-off retinal detachment with several peripheral large retinal tears."

Accordingly, the patient underwent a three-port pars plana vitrectomy (PPV) with PFCL injection (©Bausch & Lomb, DK-Line^®^ PFCL, Rochester, New York, United States), followed by laser treatment around the peripheral retinal tear edges, PFCL-air exchange, and silicone oil (5000 cSt) injection for endotamponade. Of notice that silicone oil was used because the patient had a cervical herniated disc and post-surgical positioning was not possible at the time. The patient subsequently developed a rapid progression of her cataract. Four months after the first surgery, the patient underwent combined phacoemulsification-PPV surgery with removal of silicone oil. The retina was inspected and was flat over 360 degrees.

One month after the last surgery, the patient reported reduced vision with BCVA of 20/200. The dilated fundus examination (DFE) and optical coherence tomography (OCT) showed a subretinal PFCL bubble located under the papillo-macular bundle (see [Figure 1A](#F0001){ref-type="fig"}). Consequently, two weeks later, a three-port PPV was performed to displace the bubble with the following procedure (see [[Video](http://youtu.be/Gldf3z64tS8)]{.ul},Supplemental Digital Content 1, which demonstrates the salient aspect of this technique). Retinotomies were made near the inferotemporal arcade on the nasal side and inferiorly (see [Figure 2A](#F0002){ref-type="fig"}) with a 41-gauge De Juan cannula and balanced salt solution (BSS) was injected subretinally. The vitrectomy machine was set for an automatic infusion/injection rate of 10 mmHg. The injected subretinal BSS created a serous RD that formed a pocket right under the inferotemporal arcade, which spread to reach the PFCL bubble (see [Figure 2B](#F0002){ref-type="fig"}). The purpose of this pocket is to enable the displacement of the PFCL bubble away from the papillo-macular bundle. The retina was thoroughly re-examined to ensure the absence of peripheral tears. Then, a complete air-fluid exchange was performed. Of note, the displacement of the PFCL bubble did not take place during the surgery; the patient had to remain in the upright seated position for three days to force the displacement of the bubble towards the inferior retinal periphery. The surgery had no complications. Two weeks after the procedure, BCVA improved to 20/40, the subretinal PFCL was not visible on DFE, and a control OCT confirmed displacement of the PFCL bubble with atrophy at the papillo-macular bundle (see [Figure 1B](#F0001){ref-type="fig"}). Of note, we expected to locate the subretinal PFCL bubble in the inferior retinal periphery and treat it with argon laser barricade. Although this was our original intent, we could not locate any subretinal PFCL post-operatively using indirect ophthalmoscope with scleral depression.Figure 1(**A**) Preoperative fundus photograph (left) and optical coherence tomography (OCT) image (right) showing a subretinal perfluorocarbon liquid (PFCL) bubble located under the papillo-macular bundle, due to a complication of retinal detachment (RD) surgery. (**B**) Fundus photograph (left) and OCT image (right) 2 weeks post-therapeutic inferotemporal RD induced by balanced salt solution injection, confirming displacement of the subretinal PFCL bubble with atrophy at the papillo-macular bundle.Figure 2Intraoperative photographs. Before (**A**) and after (**B**) subretinal balanced salt solution (BSS) injection using a 41-gauge De Juan cannula. Subretinal BSS created a serous retinal detachment that formed a pocket right under the inferotemporal arcade, which spread to reach the perfluorocarbon liquid bubble.

Discussion {#S0004}
==========

Retained subretinal PFCL is a complication that can generally occur in up to approximately 11% of vitreoretinal surgeries requiring intraoperative PFCL.[@CIT0003] The two risk factors that seem to be considerably associated with this complication are peripheral retinotomies larger than 120 degrees and insufficient saline rinse after removal of PFCL.[@CIT0003] Garcia-Valuenza et al[@CIT0003] found subretinal PFCL in 40% of eyes with a 360-degree retinotomy.

Subretinal PFCL can cause acute vision loss if located near the macula. Furthermore, in the long run, submacular PFCL is toxic and causes retinal damage due to an inflammatory reaction involving macrophages with intracellular vacuoles containing PFCL.[@CIT0001] However, subretinal PFCL seems to have no impact on VA if located far from the macula.[@CIT0002] Therefore, the technically challenging removal of retained PFCL is recommended depending on its location and impact on vision, with the intent of restoring VA and preventing irreversible damage to the macular anatomy.[@CIT0002] In our case, the patient probably had subretinal PFCL under the papillo-macular bundle for several weeks before it was displaced towards the inferior retinal periphery; BCVA went from 20/200 to 20/40 just two weeks after the procedure, suggesting no severe irreversible damage occurred in that short timeframe.

Several techniques are mentioned in previous case reports, including direct aspiration of the PFCL bubble, displacement of the PFCL bubble with its subsequent removal, and displacement of the PFCL bubble without its removal.[@CIT0002] The most reported method is surgical aspiration through a retinotomy that is either next to the PFCL bubble, or directly on top of it, using a small-gauge cannula (ranging from 25- to 50-gauge).[@CIT0002] Reported complications due to the risk of trauma with the direct aspiration technique include macular hole, irreversible alteration of the RPE, and submacular hemorrhage.[@CIT0004]

In a retrospective case series of three patients, Le Tien et al[@CIT0005] reported a novel surgical technique to displace subfoveal PFCL without removing it from the subretinal space. They displaced the subfoveal PFCL droplets towards the inferior retinal periphery by creating a therapeutic RD using BSS injection during 20-gauge PPV, a technique very similar to ours.[@CIT0005] They made their therapeutic RD at the posterior pole and inferior periphery by injecting BSS with a 39-gauge flexible cannula through a retinotomy adjacent to the inferotemporal vessels.[@CIT0005] All three cases had significant improvement in postoperative BCVA, with no complications.[@CIT0005] In contrast, we used a 41-gauge cannula to inject BSS during 25-gauge PPV, which reflects the recent advances in technology and the latest equipment available at the time in order to minimize undesirable surgical outcomes.

In conclusion, the consequence of retained subretinal PFCL varies depending on the size, anatomic location in regard to the macula, and amount of time it has been in contact with retinal structures. Although the literature is scarce on this topic, in our experience and in accordance to Le Tien et al[@CIT0005]'s work, displacement of retained subretinal PFCL through therapeutic RD induced by BSS injection seems to be an effective technique with less potential complications in comparison to the more traditional approach of removal by direct aspiration.

Summary {#S0005}
=======

Management of retained subretinal perfluorocarbon liquid (PFCL), a complication of retinal detachment surgery, is recommended if visual acuity is at risk. The authors describe a case where they displaced a subretinal PFCL bubble located under the papillo-macular bundle, instead of removing it via the more traditional approach of direct aspiration.

This paper was presented once, by Marc Saab, MD at the Retina Case Conference Canada 2017. Canadian Ophthalmological Society, Le Westin Montréal, Montréal, Québec, Canada; Oct 28, 2017.
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